Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

被引:23
作者
Spira, Alexander, I [1 ]
Stewart, Mark D. [2 ]
Jones, Suzanne [3 ]
Chang, Elaine [4 ]
Fielding, Anitra [5 ]
Richie, Nicole [6 ]
Wood, Laura S. [7 ]
Thompson, Michael A. [8 ]
Jones, Lee [9 ]
Nair, Abhilasha [4 ]
Mahal, Brandon A. [10 ]
Gerber, David E. [11 ]
机构
[1] US Oncol Res, Virginia Canc Specialists, Fairfax, VA USA
[2] Friends Canc Res, Washington, DC USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] FDA, Silver Spring, MD USA
[5] AstraZeneca, Gaithersburg, MD USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[8] Advocate Aurora Hlth, Aurora Canc Care, Milwaukee, WI USA
[9] Patient & Res Advocate, Arlington, VA USA
[10] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
[11] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
关键词
AMERICAN SOCIETY; ONCOLOGY-FRIENDS; ORGAN DYSFUNCTION; PARTICIPATION; OUTCOMES; IMPACT; SEX; AGE;
D O I
10.1158/1078-0432.CCR-20-3853
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In clinical research, eligibility criteria promote patient safety and optimize the evidence generated from clinical trials. However, overly stringent eligibility criteria, including laboratory requirements, may limit enrollment, resulting in delayed trial completion and potentially limiting applicability of trial results to a general practice population. Experimental Design: Starting in 2018, a working group consisting of experts in direct patient care, the FDA, industry, and patient advocacy developed recommendations to guide the optimal use of laboratory reference ranges and testing intervals in clinical trial eligibility criteria and study procedures. The working group evaluated current eligibility criteria across different clinical trial phases and performed a literature review to evaluate the impact of and justification for laboratory test eligibility requirements and testing intervals in clinical trials. Recommendations were developed on the basis of the goals of promoting safety and optimizing the evidence generated, while also expanding eligibility and applicability, and minimizing excess burden of trial participation. Results: In general, we found little variation over time and trial phase in laboratory test requirements, suggesting that these eligibility criteria are not refined according to ongoing clinical experience. We propose recommendations to optimize the use of laboratory tests when considering eligibility criteria. Conclusions: Tailoring the use of laboratory test requirements and testing intervals may increase the number and diversity of patients in clinical trials and provide clinical data that more closely represent the general practice populations.
引用
收藏
页码:2416 / 2423
页数:8
相关论文
共 34 条
[1]  
Adriaansen Melanie J., 2017, New Zealand Journal of Medical Laboratory Science, V71, P101
[2]   Rethinking the therapeutic misconception: social justice, patient advocacy, and cancer clinical trial recruitment in the US safety net [J].
Burke, Nancy J. .
BMC MEDICAL ETHICS, 2014, 15
[3]   THE RELATIONSHIP BETWEEN THE CLINICAL PRESENTATION AND SPREAD OF COLON CANCER IN 315 CONSECUTIVE PATIENTS - A SIGNIFICANT TREND OF EARLIER CANCER-DETECTION FROM 1982 THROUGH 1988 AT A UNIVERSITY HOSPITAL [J].
CAPPELL, MS ;
GOLDBERG, ES .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1992, 14 (03) :227-235
[4]  
CAVALIERI TA, 1992, GERIATRICS-US, V47, P66
[5]   Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer [J].
Cenik, Bercin Kutluk ;
Sun, Han ;
Gerber, David E. .
LUNG CANCER, 2013, 80 (03) :326-332
[6]  
Duke-Margolis Center for Health Policy, EV INCL EXCL CRIT CL
[7]   THE INFLUENCE OF INITIAL HEMOGLOBIN AND BLOOD-PRESSURE LEVELS ON RESULTS OF RADIATION-THERAPY FOR CARCINOMA OF THE PROSTATE [J].
DUNPHY, EP ;
PETERSEN, IA ;
COX, RS ;
BAGSHAW, MA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (05) :1173-1178
[8]  
FDA, REV GUID COND CLIN S
[9]  
fda, FDA guidance document
[10]   Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity [J].
Garcia, Sandra ;
Bisen, Ajit ;
Yan, Jingsheng ;
Xie, Xian-Jin ;
Ramalingam, Suresh ;
Schiller, Joan H. ;
Johnson, David H. ;
Gerber, David E. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (10) :1489-1495